Equities research analysts expect Cascadian Therapeutics, Inc. (NASDAQ:CASC) to announce earnings of ($0.29) per share for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Cascadian Therapeutics’ earnings. Cascadian Therapeutics posted earnings of ($0.47) per share during the same quarter last year, which would indicate a positive year over year growth rate of 38.3%. The company is scheduled to issue its next quarterly earnings report on Thursday, March 8th.
On average, analysts expect that Cascadian Therapeutics will report full-year earnings of ($1.27) per share for the current fiscal year, with EPS estimates ranging from ($1.53) to ($1.14). For the next year, analysts forecast that the business will report earnings of ($1.03) per share, with EPS estimates ranging from ($1.22) to ($0.69). Zacks’ EPS calculations are an average based on a survey of sell-side research analysts that follow Cascadian Therapeutics.
Cascadian Therapeutics (NASDAQ:CASC) last announced its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.28) EPS for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.01. During the same period in the previous year, the business posted ($0.09) earnings per share.
CASC has been the subject of a number of research analyst reports. Zacks Investment Research raised Cascadian Therapeutics from a “hold” rating to a “buy” rating and set a $4.50 price target for the company in a research note on Monday, November 13th. Cowen reaffirmed a “buy” rating on shares of Cascadian Therapeutics in a research note on Wednesday, August 9th. Cantor Fitzgerald reiterated a “hold” rating and issued a $4.00 price objective on shares of Cascadian Therapeutics in a report on Thursday, August 31st. ValuEngine downgraded Cascadian Therapeutics from a “sell” rating to a “strong sell” rating in a report on Friday, September 1st. Finally, Barclays began coverage on Cascadian Therapeutics in a report on Wednesday, September 6th. They issued an “underweight” rating and a $4.00 price objective for the company. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and three have assigned a buy rating to the stock. Cascadian Therapeutics presently has a consensus rating of “Hold” and a consensus price target of $5.63.
Large investors have recently modified their holdings of the company. State of Wisconsin Investment Board purchased a new stake in shares of Cascadian Therapeutics during the second quarter valued at $104,000. New York State Common Retirement Fund purchased a new stake in shares of Cascadian Therapeutics during the second quarter valued at $136,000. BB&T Securities LLC purchased a new stake in shares of Cascadian Therapeutics during the second quarter valued at $143,000. Rhumbline Advisers purchased a new stake in shares of Cascadian Therapeutics during the second quarter valued at $143,000. Finally, Bank of America Corp DE boosted its position in shares of Cascadian Therapeutics by 2,316.5% during the first quarter. Bank of America Corp DE now owns 37,528 shares of the biopharmaceutical company’s stock valued at $155,000 after buying an additional 35,975 shares during the last quarter. Hedge funds and other institutional investors own 80.35% of the company’s stock.
Shares of Cascadian Therapeutics (NASDAQ CASC) traded down $0.13 during mid-day trading on Thursday, reaching $3.92. The company had a trading volume of 544,900 shares, compared to its average volume of 297,120. Cascadian Therapeutics has a 12 month low of $3.18 and a 12 month high of $6.72.
Cascadian Therapeutics Company Profile
Cascadian Therapeutics, Inc, formerly Oncothyreon Inc, is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutic products for the treatment of cancer. The Company’s clinical-stage product candidate includes ONT-380, an orally active and selective small-molecule human epidermal growth factor receptor (HER) 2 inhibitor.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cascadian Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cascadian Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.